ASCO 2023 | Estimating long-term outcomes in patients with cHL using an oncology simulation model
Tycel Phillips, MD, City of Hope, Duarte, CA, discusses findings from a simulation model used to evaluate long-term outcomes in patients with classic Hodgkin lymphoma (cHL) using data from the ECHELON-1 trial (NCT01712490). Dr Phillips describes the aim of this model, which was to estimate outcomes in patients receiving the A+AVD regimen (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) as frontline therapy, and further explains how this may be beneficial to younger patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
